000			02265 a2200637 4500
005			20250518081855.0
264		0	_c20210423
008			202104s 0 0 eng d
022			_a2045-7634
024	7		_a10.1002/cam4.2826 _2doi
040			_aNLM _beng _cNLM
100	1		_aOoki, Akira
245	0	0	_aPatient-reported symptom burden as a prognostic factor in treatment with first-line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: Results of Phase II QUACK trial. _h[electronic resource]
260			_bCancer medicine _c03 2020
300			_a1779-1789 p. _bdigital
500			_aPublication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
650	0	4	_aAged
650	0	4	_aAntineoplastic Combined Chemotherapy Protocols _xadministration & dosage
650	0	4	_aCetuximab _xadministration & dosage
650	0	4	_aColorectal Neoplasms _xcomplications
650	0	4	_aDrug-Related Side Effects and Adverse Reactions _xdiagnosis
650	0	4	_aFemale
650	0	4	_aHumans
650	0	4	_aKaplan-Meier Estimate
650	0	4	_aMale
650	0	4	_aMiddle Aged
650	0	4	_aPatient Reported Outcome Measures
650	0	4	_aPrognosis
650	0	4	_aProgression-Free Survival
650	0	4	_aProspective Studies
650	0	4	_aQuality of Life
650	0	4	_aResponse Evaluation Criteria in Solid Tumors
650	0	4	_aSelf Report _xstatistics & numerical data
650	0	4	_aSeverity of Illness Index
700	1		_aMorita, Satoshi
700	1		_aIwamoto, Shigeyoshi
700	1		_aHara, Hiroki
700	1		_aTanioka, Hiroaki
700	1		_aSatake, Hironaga
700	1		_aKataoka, Masato
700	1		_aKotaka, Masahito
700	1		_aKagawa, Yoshinori
700	1		_aNakamura, Masato
700	1		_aShingai, Tatsushi
700	1		_aIshikawa, Masashi
700	1		_aMiyake, Yasuhiro
700	1		_aSuto, Takeshi
700	1		_aHashiguchi, Yojiro
700	1		_aYabuno, Taichi
700	1		_aSakamoto, Junichi
700	1		_aTsuji, Akihito
700	1		_aAndo, Masahiko
700	1		_aYamaguchi, Kensei
773	0		_tCancer medicine _gvol. 9 _gno. 5 _gp. 1779-1789
856	4	0	_uhttps://doi.org/10.1002/cam4.2826 _zAvailable from publisher's website
999			_c30542306 _d30542306